secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioNexus Gene Lab Corp (BGLC)
CIK:        0001737523
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001477932-25-008137
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioNexus files $100M shelf, enters $20M ATM with Maxim Group
------------------------------------------------------------

- Enters Equity Distribution Agreement with Maxim Group LLC to sell up to $20M of common stock via ATM.
- Filed S-3 shelf registration registering up to $100M of securities, not yet effective.
- Proceeds to support growth initiatives: term sheets with Fidelion Diagnostics (VitaGuard MRD) and BirchBioMed Inc.
- Company focuses on precision diagnostics, gene-based technologies in Asia and U.S.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737523/000147793225008137/0001477932-25-008137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737523/000147793225008137/bglc_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-25-008137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer